Q-omics provides the consensus-scored VN1R53P profile across patient tissues and cancer cell-line models. VN1R53P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VN1R53P is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, VN1R53P RNA expression shows 6,743 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where VN1R53P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VN1R53P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VN1R53P survival associations across molecular data types. VN1R53P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VN1R53P RNA expression–survival associations across cancer types. High VN1R53P expression shows unfavorable associations in KIRC, TGCT, LIHC, UCS and THCA, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for VN1R53P RNA expression.
This table summarizes VN1R53P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for VN1R53P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VN1R53P shows higher tumor expression in HNSC and KICH. The HNSC box plot shows higher VN1R53P RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .014).
This table shows molecular features associated with VN1R53P in patient tissues and cancer cell lines. In patient samples, VN1R53P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
